22. 6. 2018

Národný onkologický ústav
Klenová 1
Bratislava

SOLEN, s.r.o.

Slovenská onkologická spoločnosť

10 €
Registračný poplatok zahŕňa: účasť na odbornom programe, kongresové materiály (taška, program, abstrakty) a stravu počas podujatia.
Uhradený registračný poplatok je nevratný.

Odborné podujatie je zaradené do kontinuálneho medicínskeho vzdelávania.
Registrovaní účastníci dostanú na záver podujatia potvrdenie o účasti s kreditmi CME.

Odborný program

8.00 – 8.30 Registrácia/Registration

8.30 – 8.35 Privítanie/Welcome

Prezident Slovenskej onkologickej spoločnosti /President of Slovak Oncology Society, Tomáš Šálek

8.35 – 9.40 I. Genitourinárne a gynekologické nádory - Gynecologic/Genitourinary Cancer

Predsedníctvo/Chairmen: Jozef Mardiak, Michal Mego

8.35 – 8.55 1. Genitourinárne nádory/Genitourinary Cancer (Michal Mego, NOÚ, Bratislava)

1. Abstract # 228137 (4500) Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. (David F. McDermott)
2. Abstract # 224085 (4511) Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (Bernard Escudier)
3. Abstract # 220283 (LBA3) Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma. Results of a phase III noninferiority trial. (Arnaud Mejean)
4. Abstract # 222709 (5000) A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. (Pirkko-Liisa Irmeli Kellokumpu-Lehtinen)
5. Abstract # LBA 222949 (5001) Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. (Wolfgang Fendler)
6. Abstract # 216263 (5003) Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial. (Noel Clarke)
7. Abstract # 224563 (5007) KEYNOTE-199: Pembrolizumab (pembro) for docetaxelrefractory metastatic castration-resistant prostate cancer (mCRPC). (Johann S. De Bono)
8. Abstract # 4503 First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). (Arlene Siefker-Radtke)

8.55 – 9.15 2. Gynekologické nádory/Gynecologic Cancer (Zuzana Pribulová, VOÚ, Košice)

1. Abstract # 214703 (5500) Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. (Takashi ONDA)
2. Abstract # 218829 (5505) Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. (Martee Leigh Hensley)
3. Abstract # 219561 (5506) Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. (Sandro Pignata)
4. Abstract # 220873 (5508) Cost‐effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib and pembrolizumab. (Juliet Elizabeth Wolford)

9.15 – 9.40 Diskusia/Discussion

9.40 – 10.50 II. Nádory pľúc/Starostlivosť o pacientaLung Cancer/Patient and Survivor Care

Predsedníctvo/Chairmen: Peter Beržinec, Peter Kasan

9.40 – 10.10 3. Nádory pľúc/Lung Cancer (Nasser Hanna, Indiana University School of Medicine)

1. Abstract # 224733 (8502) Pragmatic study of a lymph node (LN) collection kit for nonsmall cell lung cancer (NSCLC) resection. (Raymond U. Osarogiagbon)
2. Abstract # 212261 (8503) DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma. First results. (Anna K. Nowak)
3. Abstract # 218555 (8506) Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (Hyun Cheol Chung)
4. Abstract # 216691 (8507) Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. (David Paul Carbone)
5. Abstract # 228023 (105) Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). (Luis G. Paz-Ares)
6. Abstract # 214607 (LBA9000) IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (Robert M. Jotte)
7. Abstract # 229709 (9001) Nivolumab (Nivo) + platinum‐doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. (Hossein Borghaei)
8. Abstract # 212527 (9006) Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. (Naoki Furuya)
9. Abstract #226263 (LBA4) Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. (Gilberto Lopes)

10.10 – 10.25 4. Starostlivosť o pacienta/Patient and Survivor Care (Andrea Škripeková, NOÚ, Bratislava)

1. Abstract # 221581 (10000) Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). (Sherry Shen)
2. Abstract # 220993 (10001) The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial. (Jun J. Mao)
3. Abstract # 218571 (LBA10003) Improving communication with older patients with cancer using geriatric assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT). (Supriya Gupta Mohile)
4. Abstract # 220939 (10005) Randomized trial of a symptom monitoring intervention for hospitalized patients with cancer. (Charn-Xin Fuh)

10.25 – 10.50 Diskusia/Discussion

10.50 – 11.05 Prestávka/Coffee-Break

11.05 – 12.05 III. Malígny melanóm/Nádory hlavy a krkuMalignant Melanoma/Head&Neck Cancer

Predsedníctvo/Chairmen: Klaudia Gočárová, Richard Hrubý

11.05 – 11.25 5. Malígny melanóm/Malignant Melanoma (Robert Godál, NOÚ, Bratislava)

1. Abstract # 220309 (108) Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-‐ 301/KEYNOTE-252 study. (Georgina V. Long)
2. Abstract # 216115 (9501) Final analysis of DECOG-‐ SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. (Ulrike M. Leiter)
3. Abstract # 214567 (9502) Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). (Jeffrey S. Weber)
4. Abstract # 223875 (9504) Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (Reinhard Dummer)

11.25 – 11.45 6. Nádory hlavy a krku/Head&Neck Cancer (Pavol Dubinský, VOÚ, Košice)

1. Abstract # 225943 (6000) Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck. (Vijay Maruti Patil)
2. Abstract # 212633 (6006) Results of a randomized, placebo (PBO) controlled, doubleblind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP). (Carryn M. Anderson)
3. Abstract # 228507 (6008) Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC). (Douglas Adkins)
4. Abstract # 223041 (6009) A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). (Sean Matthew McBride)

11.45 – 12.05 Diskusia/Discussion

12.05 – 13.10 IV. Karcinóm prsníka/Breast Cancer

Predsedníctvo/Chairmen: Mária Wagnerová, Juraj Beniak

12.05 – 12.25 7. Metastatický karcinóm prsníka/Breast Cancer – Metastatic (Marián Streško, FN Trnava)

1. Abstract # LBA 218409 (1000) Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. (Dennis J. Slamon)
2. Abstract # 212871 (1005) Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open label phase 2 study. (Guy Heinrich Maria Jerusalem)
3. Abstract # 216233 (LBA1006) Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (Jose Baselga)
4. Abstract # 217073 (1007) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, doubleblind, placebo-controlled, phase II trial. (Peter Schmid)

12.25 – 12.45 8. Karcinóm prsníka – lokálna/regionálna/adjuvantná liečba/Breast Cancer – Local/Regional/Adjuvant (Juraj Beniak, POKO Poprad)

1. Abstract # 221713 (104) Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (Sibylle Loibl)
2. Abstract # 222747 (500) Adjuvant Denosumab in Early Breast Cancer - Disease-Free Survival Analysis of 3,425 Postmenopausal Patients in the ABCSG-18 Trial. (Michael Gnant)
3. Abstract # 217191 (506) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. (Helena Margaret Earl)
4. Abstract # 212997 (LBA1) TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2‐negative, node-negative breast cancer and an intermediate prognosis 21‐gene recurrence score. (Joseph A. Sparano)

12.45 – 13.10 Diskusia/Discussion

13.10 – 14.10 Obed/Lunch

14.10 – 15.15 V. Gastrointestinálne nádory/Gastrointestinal Cancer

Predsedníctvo/Chairmen: Tomáš Šálek, Radovan Barilla

14.10 – 14.30 9. Gastrointestinálne (kolorektálne) nádory/Gastrointestinal (Colorectal) Cancer (Silvia Jurišová, NOÚ, Bratislava)

1. Abstract # 221135 (3501) Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. (Yong Sang Hong)
2. Abstract # 222851 (LBA3503) A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. (François Quenet)
3. Abstract # 219385 (3505) First-line FOLFOX plus panitumumab (Pan) followed by 5FU/ LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (Filippo Pietrantonio)
4. Abstract # 220001 (3514) KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. (Dung T. Le)

14.30 – 14.50 10. Gastrointestinálne (nekolorektálne) nádory/Gastrointestinal (Non-Colorectal) Cancer (Branislav Bystrický, FN Trenčín)

1. Abstract # 218335 (LBA4001) Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. (Thierry Conroy)
2. Abstract # 231377 (4004) A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). (Pamela L. Kunz)
3. Abstract # 222777 (LBA4008) Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. (Janusz Jankowski)
4. Abstract # 226915 (4019) Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. (Ghassan K. Abou-Alfa)

14.50 – 15.15 Diskusia/Discussion

15.15 – 15.20 Záver/Closing

Prezident Slovenskej onkologickej spoločnosti/President of Slovak Oncology Society, Tomáš Šálek

O možnostiach ubytovania sa informujte mailom u organizátora: Mgr. Andrej Šutka, kongres@solen.sk

SOLEN, s.r.o.

Ambrova 5

831 01 Bratislava

Tel. 02/5413 1365

www.solen.sk

kongres@solen.sk

Monika Horáková, 0903 452 654, horakova@solen.sk